AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
AAPL   323.60 (+0.08%)
MSFT   184.20 (-0.38%)
AMZN   2,466.73 (-0.23%)
NVDA   349.26 (-1.09%)
MU   48.04 (+2.61%)
GE   7.25 (+2.84%)
AMD   52.50 (-1.94%)
ACB   14.36 (-1.03%)
GILD   73.80 (+0.74%)
DIS   121.80 (+2.57%)
NFLX   419.92 (-1.73%)
BA   168.10 (+9.70%)
Log in

NASDAQ:IFRXInflarx Stock Price, Forecast & News

$7.99
-0.45 (-5.33 %)
(As of 06/3/2020 12:04 PM ET)
Add
Compare
Today's Range
$7.92
Now: $7.99
$8.55
50-Day Range
$5.03
MA: $6.95
$8.96
52-Week Range
$2.17
Now: $7.99
$37.47
Volume18,864 shs
Average Volume900,466 shs
Market Capitalization$208.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.62
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Read More
Inflarx logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.9Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IFRX
CUSIPN/A
CIKN/A
Phone49-36-4150-8180

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share

Profitability

Net Income$-59,650,000.00

Miscellaneous

Employees36
Market Cap$208.54 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

Inflarx (NASDAQ:IFRX) Frequently Asked Questions

How has Inflarx's stock been impacted by COVID-19 (Coronavirus)?

Inflarx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IFRX stock has increased by 148.3% and is now trading at $8.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Inflarx?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 2 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inflarx.

When is Inflarx's next earnings date?

Inflarx is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Inflarx.

How were Inflarx's earnings last quarter?

Inflarx NV (NASDAQ:IFRX) released its earnings results on Thursday, May, 21st. The company reported ($0.35) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.20. View Inflarx's earnings history.

What price target have analysts set for IFRX?

9 brokerages have issued 12-month target prices for Inflarx's shares. Their forecasts range from $5.00 to $20.00. On average, they expect Inflarx's stock price to reach $8.38 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View analysts' price targets for Inflarx.

Has Inflarx been receiving favorable news coverage?

News coverage about IFRX stock has been trending neutral on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Inflarx earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutInflarx.

Are investors shorting Inflarx?

Inflarx saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 865,100 shares, a drop of 19.9% from the April 30th total of 1,080,000 shares. Based on an average daily trading volume, of 1,360,000 shares, the short-interest ratio is presently 0.6 days. Currently, 5.0% of the company's stock are short sold. View Inflarx's Current Options Chain.

Who are some of Inflarx's key competitors?

What other stocks do shareholders of Inflarx own?

Who are Inflarx's key executives?

Inflarx's management team includes the following people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)
  • Mr. Arnd Christ, Chief Financial Officer (Age 53)
  • Mr. Jason M. Marks J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy

When did Inflarx IPO?

(IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is Inflarx's stock symbol?

Inflarx trades on the NASDAQ under the ticker symbol "IFRX."

Who are Inflarx's major shareholders?

Inflarx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (4.09%), FNY Investment Advisers LLC (1.43%), Ikarian Capital LLC (1.01%), Morgan Stanley (0.41%), Geode Capital Management LLC (0.35%) and Two Sigma Advisers LP (0.32%).

Which major investors are selling Inflarx stock?

IFRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, FNY Investment Advisers LLC, Ikarian Capital LLC, and Two Sigma Advisers LP.

Which major investors are buying Inflarx stock?

IFRX stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Spark Investment Management LLC, BlackRock Inc., and Geode Capital Management LLC.

How do I buy shares of Inflarx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inflarx's stock price today?

One share of IFRX stock can currently be purchased for approximately $8.02.

How big of a company is Inflarx?

Inflarx has a market capitalization of $209.32 million. The company earns $-59,650,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Inflarx employs 36 workers across the globe.

What is Inflarx's official website?

The official website for Inflarx is www.inflarx.de.

How can I contact Inflarx?

Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.